Name: SD-436
Brand: BOC Sciences
Price: 1999 USD
Availability: MadeToOrder

Size

Price

Stock

Quantity

25 mg

$1999

In stock

Purity

≥95%

Appearance

White to off-white solid

Storage

Store at -20 °C

IUPACName

[[2-[[(5S,8S,10aR)-8-[[(2S)-5-amino-1-[[(2S)-3-(3,4-difluorophenyl)-1-[4-[4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]but-3-ynyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]-3-methoxycarbonyl-6-oxo-1,2,4,5,8,9,10,10a-octahydropyrrolo[1,2-a][1,5]diazocin-5-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid

Synonyms

SD 436; SD436

Density

1.554±0.10 g/cm3 (Predicted)

InChI Key

FLMMCKAIYLDKIN-PBKIRHPCSA-N

InChI

InChI=1S/C58H62F4N9O14PS/c1-85-57(81)69-24-21-36-11-14-45(71(36)56(80)43(30-69)66-53(77)47-28-34-27-35(10-16-46(34)87-47)58(61,62)86(82,83)84)52(76)64-41(13-17-48(63)72)50(74)65-42(26-32-9-12-39(59)40(60)25-32)55(79)68-22-19-31(20-23-68)5-2-3-6-33-7-4-8-37-38(33)29-70(54(37)78)44-15-18-49(73)67-51(44)75/h4,7-10,12,16,25,27-28,31,36,41-45H,2,5,11,13-15,17-24,26,29-30H2,1H3,(H2,63,72)(H,64,76)(H,65,74)(H,66,77)(H,67,73,75)(H2,82,83,84)/t36-,41+,42+,43+,44?,45+/m1/s1

SMILES

COC(=O)N1CC[C@H]2CC[C@H](N2C(=O)[C@H](C1)NC(=O)C3=CC4=C(S3)C=CC(=C4)C(F)(F)P(=O)(O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC5=CC(=C(C=C5)F)F)C(=O)N6CCC(CC6)CCC#CC7=C8CN(C(=O)C8=CC=C7)C9CCC(=O)NC9=O

Mechanism

Target: Targets STAT3 transcription factor for experimental targeted protein degradation studies.

Binding Site: Binds the STAT3 SH2 phosphotyrosine-binding domain and cereblon thalidomide-binding pocket to support productive ternary complex formation.

Mechanism of Action: SD-436 is designed for use in PROTAC or targeted protein degradation experiments directed toward STAT3 transcription factor. The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.

Applications

• PROTAC-Mediated Cancer Research: SD-436 is utilized in cancer research to selectively degrade oncogenic proteins, offering a novel approach to target proteins traditionally considered "undruggable." This facilitates the study of cancer cell proliferation and survival pathways, providing insights into potential therapeutic targets for drug development.

• Targeted Degradation in Neurodegenerative Disorders: By employing SD-436, researchers can investigate the degradation of neurodegenerative disease-related proteins. This application aids in understanding protein aggregation mechanisms and exploring new treatment strategies for conditions like Alzheimer's and Parkinson's disease.

• Selective Protein Knockdown Studies: SD-436 serves as a powerful tool for selectively degrading specific proteins within cellular systems, enabling researchers to dissect protein function and interactions. This application is critical for elucidating cellular pathways and understanding disease mechanisms at a molecular level.

• Drug Resistance Mechanism Exploration: Utilizing SD-436 allows for the targeted degradation of proteins associated with drug resistance. This application aids in identifying resistance pathways and developing strategies to overcome resistance in various disease models, enhancing the effectiveness of existing therapies.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂